Evotec stock heads toward November 5 results after outlook reaffirmed

Published on 11/02/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock heads toward a key results date on November 5 after preliminary figures topped market expectations. The full outlook remains unchanged.

Results Date Frames Near-Term Focus

Evotec will publish complete third-quarter and first-nine-month results on Thursday, November 5, 2026.
Preliminary nine-month revenue reached EUR 465.0 million, while adjusted EBITDA was negative EUR 42.8 million.
Management reaffirmed full-year revenue guidance of EUR 570 million to EUR 610 million and adjusted EBITDA guidance of negative EUR 70 million to negative EUR 105 million.

Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec is approaching its next operating checkpoint with complete third-quarter and first-nine-month results due on Thursday, November 5, 2026. The company had already released preliminary figures on October 13, saying revenue and adjusted EBITDA were above current market expectations.

In the preliminary release, Evotec expected Group revenue of EUR 465.0 million for the first nine months of 2026. Adjusted Group EBITDA was expected at negative EUR 42.8 million. The company said the variance versus consensus was driven largely by the phasing of analyst estimates, which leaves the November report important for assessing the underlying development rather than just the initial top-line surprise. The figures and timing are reproduced in the StockTitan filing.

Guidance Remains The Main Test

Evotec reaffirmed full-year 2026 revenue guidance of EUR 570 million to EUR 610 million. At constant exchange rates, the range is EUR 595 million to EUR 635 million. Adjusted EBITDA guidance remains negative EUR 70 million to negative EUR 105 million, or negative EUR 60 million to negative EUR 90 million at constant exchange rates.

The nine-month revenue indication therefore sets a clear frame for the final quarter, while the continuing adjusted EBITDA loss keeps profitability and cash conversion central to the upcoming update. Investors will look for the full quarterly figures, the split between business areas and any change in the outlook after the preliminary release left the annual targets intact.

The real-time quote of Evotec stock was 2.81 euros on Lang & Schwarz at 10:15 CET on Monday, November 2, 2026, 0.35 percent below the Xetra close of Friday, October 30. The comparison uses the preceding Xetra session because the November 2 trading session was still open.

Germany's equity market provides the broader setting for the biotechnology share through the DAX market environment.

For investors, the November 5 publication should clarify whether the preliminary improvement versus consensus reflects operating momentum or mainly the timing of estimates. Evotec's unchanged annual targets and still-negative adjusted EBITDA range make the management update and any comments on the final quarter the next near-term catalysts.

More developments are available in more news and analyses on Evotec stock.